IN2014CN04671A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04671A
IN2014CN04671A IN4671CHN2014A IN2014CN04671A IN 2014CN04671 A IN2014CN04671 A IN 2014CN04671A IN 4671CHN2014 A IN4671CHN2014 A IN 4671CHN2014A IN 2014CN04671 A IN2014CN04671 A IN 2014CN04671A
Authority
IN
India
Prior art keywords
compounds
poly
pharmaceutical compositions
present
treating diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Gianluca Mariano Enrico Papeo
Alessandra Cirla
Matteo D’ANELLO
Alessandra Scolaro
Fabio Zuccotto
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47227787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN04671(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of IN2014CN04671A publication Critical patent/IN2014CN04671A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4671CHN2014 2011-11-25 2012-11-20 IN2014CN04671A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190687 2011-11-25
EP12161489 2012-03-27
PCT/EP2012/073125 WO2013076090A1 (en) 2011-11-25 2012-11-20 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors

Publications (1)

Publication Number Publication Date
IN2014CN04671A true IN2014CN04671A (cg-RX-API-DMAC7.html) 2015-09-18

Family

ID=47227787

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4671CHN2014 IN2014CN04671A (cg-RX-API-DMAC7.html) 2011-11-25 2012-11-20

Country Status (14)

Country Link
US (1) US9422243B2 (cg-RX-API-DMAC7.html)
EP (1) EP2788328B1 (cg-RX-API-DMAC7.html)
JP (1) JP6106182B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140097457A (cg-RX-API-DMAC7.html)
CN (1) CN103946214B (cg-RX-API-DMAC7.html)
AU (1) AU2012342562B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012031A2 (cg-RX-API-DMAC7.html)
CA (1) CA2856759A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014001323A1 (cg-RX-API-DMAC7.html)
EA (1) EA027800B1 (cg-RX-API-DMAC7.html)
ES (1) ES2676068T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN04671A (cg-RX-API-DMAC7.html)
MX (1) MX2014006015A (cg-RX-API-DMAC7.html)
WO (1) WO2013076090A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346147B (es) 2012-03-07 2017-03-09 Inst Of Cancer Research: Royal Cancer Hospital (The) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
US9611223B2 (en) 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
JP6663350B2 (ja) * 2014-01-16 2020-03-11 クロヴィス・オンコロジー,インコーポレーテッド ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのparp阻害剤の使用
BR112018008630A2 (pt) 2015-11-06 2018-10-30 Neurocrine Biosciences Inc derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica
ES2983860T3 (es) 2019-12-06 2024-10-25 Neurocrine Biosciences Inc Antagonistas del receptor muscarínico 4 y métodos de uso
CN119317434A (zh) 2022-06-15 2025-01-14 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024231548A1 (en) 2023-05-11 2024-11-14 Astrazeneca Ab Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090334A1 (en) * 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
MXPA05000983A (es) * 2002-07-24 2005-08-18 Kyorin Seiyaku Kk Derivados de 4-(aril substituido)-5-hidroxiisoquinolinona.
JP5411152B2 (ja) * 2008-02-22 2014-02-12 Msd株式会社 オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉-1(2h)-酮衍生物

Also Published As

Publication number Publication date
US9422243B2 (en) 2016-08-23
US20140336192A1 (en) 2014-11-13
KR20140097457A (ko) 2014-08-06
BR112014012031A2 (pt) 2017-05-30
CL2014001323A1 (es) 2014-09-05
EA027800B1 (ru) 2017-09-29
EP2788328B1 (en) 2018-01-31
AU2012342562B2 (en) 2017-02-23
WO2013076090A1 (en) 2013-05-30
CA2856759A1 (en) 2013-05-30
HK1200166A1 (en) 2015-07-31
AU2012342562A1 (en) 2014-07-10
JP6106182B2 (ja) 2017-03-29
CN103946214B (zh) 2016-08-17
EA201491026A1 (ru) 2014-11-28
MX2014006015A (es) 2014-06-04
EP2788328A1 (en) 2014-10-15
JP2014533709A (ja) 2014-12-15
ES2676068T3 (es) 2018-07-16
CN103946214A (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
MX362939B (es) Derivados de (aza-)isoquinolinona.
MX367425B (es) Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
MX2014013090A (es) Derivados de pirrolotriazinona.
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
NZ700928A (en) Dna-pk inhibitors
IN2014MN01875A (cg-RX-API-DMAC7.html)
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
IN2014CN04671A (cg-RX-API-DMAC7.html)
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
MX2016001536A (es) Derivados de urea de piperidinas.
MX364859B (es) Derivados de imidazopirazinona.
MX369393B (es) Derivados de ftalazina.
DOP2014000141A (es) Derivados de quinolina como inhibidores de la enzima pde10a
MX2016001934A (es) Derivados de ciclopentilamina 3-sustituidos.
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors